Brief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
26/03/2024 12:08
March 26 (Reuters) - Ayala Pharmaceuticals Inc
ADXS.PK :
* AYALA PHARMACEUTICALS ANNOUNCES COMPLETION OF SALE OF
AL102 TO
IMMUNOME
Source text for Eikon: ID:nGNX3WWPrz
Further company coverage: ADXS.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors